A new study reports that GLP-1 medications may improve low testosterone in men with obesity or type 2 diabetes. The findings ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

Migraines are one of the world's most common neurological conditions, impacting nearly 15% of people globally. Despite this widespread impact, many sufferers find current preventive treatments ...

Pharmacy benefit manager CVS Caremark drops Zepbound coverage, estimating 10-15% savings while Eli Lilly offers self-pay ...

Reduced monthly costs for uninsured patients still amount to around $500. That can put the drugs out of reach for many.

Some online pharmacies sell semaglutide and tirzepatide that are ineffective, unsafe, or an outright scam. Here’s how to find ...

Key Points It isn't easy finding high-yield dividend growth stocks when the market is at an all-time high.Shares of Novo Nordisk and UnitedHealth Group have been beaten down to less than half their ...

Key Points Pfizer and Novo Nordisk have underperformed the market over the past year.But both should remain major players in ...

CHICAGO — Dapiglutide, a novel GLP-1/GLP-2 receptor agonist, was associated with body weight reductions of up to 8.3% at 13 weeks for patients with overweight or obesity in an early study ...

GLP-1 and GLP-2 coinfusion resulted in net increased lipid absorption and an increase in TRL-TG and apoB48. However, prolonged (120-min) coinfusion of GLP-1 and GLP-2 decreased postprandial lipemia.